Received: October 15, 2018
Accepted: September 15, 2018
Mediterr J Hematol Infect Dis 2018, 10(1): e2018066 DOI 10.4084/MJHID.2018.066
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
incorporates a broad clinical spectrum characterized by decreased or
absent production of normal hemoglobin leading to decreased red blood
cell survival and ineffective erythropoiesis. Chronic iron overload
remains an inevitable complication resulting from regular blood
transfusions (transfusion-dependent) and/or increased iron absorption
(mainly non-transfusion-dependent thalassemia), requiring adequate
treatment to prevent the significant associated morbidity and
mortality. Iron chelation therapy has become a cornerstone in the
management of thalassemia patients, leading to improvements in their
outcome and quality of life. Deferasirox (DFX), an oral iron chelating
agent, is approved for use in transfusion dependent and
non-transfusion-dependent thalassemia and has shown excellent efficacy
in this setting. We herein present an updated review of the role of
deferasirox in thalassemia, exploring over a decade of experience,
which has documented its effectiveness and convenience; in addition to
its manageable safety profile.
Pathophysiology of IOL in Thalassemia
Diagnosis and Quantification of IOL
Pharmacokinetics of DFX
Evidence in TDT
Monotherapy. DFX at 20 mg/kg/d had shown similar efficacy to DFO at 40 mg/kg/d in reducing LIC. The prospective ESCALTOR trial reported sustained reduction in LPI levels in a group of β- thalassemia patients with significant IOL with a mean decrease in LIC by 3.8 mg iron/g dw, and SF by 517 ng/ml.[30,36] Two-year treatment with DFX leads to a reduction of iron levels in those whose baseline LIC ≥7 mg iron/g dw while maintaining iron levels in those with baseline LIC < 7 mg/g dw. An initial phase II trial in pediatric patients with TDT had shown that low doses of DFX were associated with limited efficacy. These results were also replicated in a large randomized phase III study including 586 pediatric and adult patients with β-thalassemia who achieved a significant reduction in SF and LIC with DFX at doses of 20-30 mg/kg/d, while doses of 10 mg/kg/d showed inadequate efficacy in regularly transfused patients. Sustained improvements in iron burden were noted with follow up to 5 years, where 83% achieved SF ≤2500 ng/ml, 47.3% of patients reaching SF≤1000 ng/ml after 4 years, with more than half of patients receiving a final dose of DFX ≥25 mg/kg/d during the extension period. While doses of 20 mg/kg/d have maintained an LIC below 7 mg/g dw, higher doses of around 30 mg/kg/d have been required to achieve a net reduction in iron levels in those with LIC ≥ 7 mg/g dw.[40,41] This large prospective trial included 1115 patients with β-thalassemia and showed a statistically significant decrease in SF with DFX therapy. In addition, it indicated the need to choose a starting dose that correlates with the patient’s transfusion requirements, and that needs to be titrated in a timely manner. At least three years of DFX lead to reversal or stabilization of liver fibrosis in TDT patients showing evidence of IOL. A systematic review and meta-analysis including 1520 patients with TDT also showed increases in SF at lower DFX doses, but no significant difference in the change in SF with DFX at 30 mg/kg as compared to DFO. JaiSwal et al. later reported a significant mean reduction in SF of 1207.11 ng/ml (32.38% decrease) after 12 months therapy with DFX at a mean dose of 38 mg/kg/d in 45 heavily transfused thalassemia patients. A prospective observational study including 176 patients with TDT (total 267), reported long-term results in pediatric patients treated with DFX and documented a decrease in median SF of 575 ng/ml after five years of DFX therapy with a mean dose of 25.8 mg/kg/d. A Cochrane review reported by Bollig et al. indicated similar efficacy of DFX as compared to DFO (depending on the ratio of DFX to DFO dose, generally showing similar results at a mean ratio of 1 mg of DFX to 1.8 mg of DFO).
DFX has also been effective in the management of cardiac siderosis. Wood et al. have reported an improvement in myocardial T2* in patients with severe cardiac siderosis treated for 18 months with DFX at doses up to 40 mg/kg/d (13 patients). DFX also led to normalization of cardiac T2* in 68% of patients with a baseline level of 10-20 ms, and sustained improvements with prolonged duration of therapy. The phase II CORDELIA trial documented non-inferiority of DFX compared to DFO in the management of β-thalassemia major asymptomatic patients with cardiac IOL (T2* 6-20 ms), with a 12% increase in the geometric mean (Gmean ) myocardial T2*. On the other hand, the MILE study has shown that DFX at similar doses lead to a 10% relative improvement in myocardial T2*, with the most significant results noted in those with moderate cardiac siderosis and those with lower baseline LIC, while no significant changes were reported in cases of severe cardiac iron deposition. Greater improvement in LIC and myocardial T2* were noted with higher doses of DFX (above 30 mg/kg/d). This study also showed statistically significant improvement in LIC, specifically those with baseline LIC ≥7 mg/g dw, with a statistically insignificant reduction in SF, and no major safety concerns. DFX has also resulted in the greatest improvement in the prevalence of endocrinopathy, in addition to a significant improvement noted on bone mineral density evaluation as compared to DFO, DFP and DFO combined with DFP in a retrospective study.
Safety of DFX
Less common AEs include ocular and visual disturbances, cytopenia, and Fanconi syndrome. For pediatric patients, Vichinsky et al. reported AEs with suspected relation to DFX in 39.1% of patients with nine patients having a serious AE (3.4%), with a gradual decline in the incidence of AEs over time. Osborne et al. recently reported the utilization and safety of DFX using an observational post-marketing study conducted in England. Beta-thalassemia was the second most frequent reason for prescribing DFX (26 patients; 21.3%), and increased creatinine was noted in only two patients out of 122 (1.6%). The EPIC trial had reported a 0.6% of proteinuria after 1-year follow up. Bayhana et al later evaluated the prevalence and need for monitoring of proteinuria in thalassemia patients on DFX therapy, where a retrospective single center analysis including 37 total patients (36 with thalassemia major), reported proteinuria in 7 patients (18.9%) at a mean follow up of 44 months, all of which resolved with follow up. This analysis identified younger age (below 23) and higher doses of DFX (above 29 mg/kg/d) as risk factors for the development of proteinuria. A retrospective chart review recently reported safety data for prolonged follow-up periods reaching 13 years, including 282 patients, with no significant or persistent nephrotoxicity noted and only non-progressive and reversible increases in creatinine.
DFO and DFX
DFP and DFX
DFX in the Post-transplantation Setting
DFX in NTDT
Guidelines with specific indications/thresholds have been established to determine the appropriate time for initiation, dose escalation, and termination of ICT in NTDT patients. DFX with an initial starting dose of 10 mg/kg/d should be started in patients ≥10 years of age if their LIC ≥ 5 mg iron/g dw, or if their SF concentration was found to be ≥ 800 μg/L (if LIC is not available due to MRI unavailability). To monitor iron levels, LIC should be repeated six months after therapy initiation, with follow up every 6–12 months, and SF levels should be measured every three months. If LIC levels at six months are still greater than 7 mg/g dw (or SF >1500 μg/L only if LIC is unavailable) with less than 15% reduction in baseline values, dose escalation should be considered up to 20 mg/kg/d. DFX therapy can be safely discontinued when patients reach an LIC value of 3 mg/g dry weight (or SF level of 300 μg/L only if LIC is unavailable). In the realm of NTDT, it is recommended to intensify ICT if the LIC after six months of treatment >7 mg/g dw, SF >1500–2000 ng/mL or in case of <15% decrease from baseline. Indications to stop ICT in NTDT include a SF < 300 ng/mL and/or LIC < 3 mg/g dry wt. liver.
Adherence to ICT
DFO therapy, owing largely to its cumbersome administration, has a detrimental impact on multiple areas of patients’ lives, including their emotional well-being, physical functioning, self- esteem, among others. Treatment with DFO is demanding. The drug has poor oral bioavailability and a short plasma half-life. Therefore, slow subcutaneous infusions are necessary 3–7 times weekly. Because of injection-site reactions and pain, the administration is inconvenient, and the necessary equipment is not available in many countries. These factors lead to poor compliance, which in turn leads to increased mortality. Treatment satisfaction and adherence are generally greater with oral ICT than with parenteral infusion. One study showed that adherence to oral DFX monotherapy was significantly higher than DFO infusion (96% vs. 92%; p<0.001). Adherence to oral DFX on DFO/DFX combination therapy was lower than that of monotherapy (90% vs. 96%; p<0.001). Adherence to DFO infusion on DFO/DFP combination therapy was non- significantly lower than that of monotherapy or DFO/DFX combination therapy (88% vs. 92%; p=0.25). Adherence did not significantly change over follow-up period except that an increase in adherence was seen after a change in chelation from DFO infusion to oral DFX (p=0.03, paired t- test). In a qualitative examination of the reported patient adherence over time after this iron chelator change, no evidence of a ‘honeymoon’ phase was seen, with temporary high adherence to the new chelator. In an open-ended comment section, many participants commented on the benefits of oral chelation and their improved adherence.
Another study by Cappellini et al., compared patient-reported outcomes (PROs) during receipt of DFO infusions or once-daily DFX oral therapy. PRO questionnaires were completed by patients, their parents or legal guardian at different time points: baseline, week 4, week 24, and end of study (EOS). Patients assessed their satisfaction level with study treatment (very satisfied, satisfied, neutral, dissatisfied, or very dissatisfied) and rated its convenience. At baseline, 289 and 282 patients in the DFX and DFO groups, respectively, had previous experience with DFO (7 and 8 patients, respectively were DFO-naïve); of these patients, 45.3% and 45.0%, respectively, reported that they were very satisfied or satisfied with DFO treatment, while 32.5% and 33.0% reported being dissatisfied or very dissatisfied. There were no significant differences in the satisfaction ratings between the groups at baseline. At week 4, week 24, and EOS, significantly more patients receiving DFX reported being very satisfied or satisfied with treatment compared with those receiving DFO (92.0% vs 50.4% and 89.6% vs 44.0%, respectively; P < 0.001). At each time point, more patients receiving DFO reported being dissatisfied or very dissatisfied with treatment compared with those receiving DFX (28.0% vs. 0.7% and 31.2% vs. 2.4%). When considering only those patients who responded to the question at EOS, the overall proportion of patients who were satisfied with treatment was 88.8% (246/277) for DFX and 40.5% (109/269) for DFO. Results of this study suggested that DFX had a positive impact on patients' daily lives. A recent Cochrane review exploring the interventions needed for improving adherence to ICT in patients with thalassemia or sickle cell disease concluded that real-life data is required to assess specific adherence strategies and thus make recommendations in this setting.
Recent Advances in ICT
DFX film coated tablet (FCT)
The open-label, phase II ECLIPSE study evaluated the overall safety profile, as measured by the frequency and severity of AEs and changes in laboratory values, and the pharmacokinetics (PK), and PROs of DFX FCT and DT formulations in patients aged ≥10 years with TDT or very-low-, low-, or intermediate-risk MDS, requiring ICT. The overall incidence of AEs was similar between treatments, but there were fewer serious AEs with FCT. FCT recipients consistently reported better adherence, greater satisfaction, and fewer concerns, with a safety profile consistent with the known DT formulation. Taking the dose conversion factor into account, which was required because the two formulations have differing bioavailability, patients received similar mean doses of the active ingredient in DFX. However, at the end of the 24-week trial period, FCT patients had a higher observed median absolute reduction in SF from baseline, suggesting a possible association between the treatment arm and observed efficacy. A potential explanatory factor of this difference in efficacy could be better treatment adherence among the patients receiving FCT compared with DT. These findings suggest a preference in favor of the new formulation, with better patient satisfaction and adherence translating into reduced IOL-related complications.
Table 1 includes significant trials evaluating DFX in TDT and NTDT, and figure 1A and B includes recommendations regarding chelation with DFX and suggested monitoring and/or adjustments.
|Table 1. Significant trials evaluating DFX in TDT and NTDT.|
|Figure 1A. DFX in thalassemia.|
|Figure 1B. Monitoring for and managing adverse events with DFX.|
- Rachmilewitz E and Giardina P. How I treat thalassemia. Blood 2011; 118 (13): 3479-3487. https://doi.org/10.1182/blood-2010-08-300335 PMid:21813448
- Giardina P, Forget B. Thalassemia syndromes. In: Hoffman R, Benz E, Shattil S, et al, eds. Hematology: Basic Principles and Practice (5th ed). Philadelphia, PA: Churchill Livingstone; 2008:535-563.
- Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010; 115 (22):4331-4336. https://doi.org/10.1182/blood-2010-01-251348 PMid:20233970 PMCid:PMC2881491
- Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006; 91(10): 1343- 1351. PMid:17018383
- Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998; 850:227–31. https://doi.org/10.1111/j.1749-6632.1998.tb10479.x PMid:9668544
- Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program 2017; 2017(1):265-71.
- Saliba A, Taher A. Iron overload in transfusion-dependent thalassemia. Hematology (Amsterdam, Netherlands). 2015;20(5):311- 2. https://doi.org/10.1179/1024533215Z.000000000365
- In: rd, Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). Nicosia (CY): Thalassaemia International Federation (c) 2014 Thalassaemia International Federation; 2014.
- Taher AT, Musallam KM, Wood JC, Cappellini MD. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. American Journal of Hematology. 2010;85(4):288-90. https://doi.org/10.1002/ajh.21626 PMid:20143405
- Pootrakul P, Kitcharoen K, Yansukon P, Wasi P, Fucharoen S, Charoenlarp P, et al. The effect of erythroid hyperplasia on iron balance. Blood. 1988;71(4):1124-9. PMid:3355891
- Tanno T, Miller JL. Iron Loading and Overloading due to Ineffective Erythropoiesis. Adv Hematol. 2010;2010:358283. https://doi.org/10.1155/2010/358283 PMid:20467559 PMCid:PMC2868182
- Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811-9. https://doi.org/10.1074/jbc.M008923200 PMid:11113132
- Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-33. https://doi.org/10.1182/blood-2011-01-258467 PMid:21346250 PMCid:PMC3099567
- Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-3. https://doi.org/10.1126/science.1104742 PMid:15514116
- Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037-44. https://doi.org/10.1172/JCI0215686 PMid:12370282 PMCid:PMC151151
- Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92(5):583-8. https://doi.org/10.3324/haematol.10842 PMid:17488680
- Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Haematol. 2016;172(4):512- 23. https://doi.org/10.1111/bjh.13820 PMid:26491866
- Musallam KM, Taher AT, Duca L, Cesaretti C, Halawi R, Cappellini MD. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with beta thalassemia intermedia. Blood Cells Mol Dis. 2011;47(4):232-4. https://doi.org/10.1016/j.bcmd.2011.07.005 PMid:21865063
- Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096-101. https://doi.org/10.1038/nm1629 PMid:17721544
- Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009;114(1):181-6. https://doi.org/10.1182/blood-2008-12-195503 PMid:19414861 PMCid:PMC2710947
- Taher A, El Rassi F, Isma'eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008;93(10):1584–1586. https://doi.org/10.3324/haematol.13098 PMid:18728025
- Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007;49(3):329–332). https://doi.org/10.1002/pbc.21275 PMid:17554789
- Cheng HL, Holowka S, Moineddin R, et al. Liver iron overload assessment by t *2 magnetic resonance imaging in pediatric patients: an accuracy and reproducibility study. Am J Hematol. 2012;87(4):435–437. https://doi.org/10.1002/ajh.23114 PMid:22286974
- Kirk P, Roughton M, Porter JB, et al. Cardiac t2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961–1968. https://doi.org/10.1161/CIRCULATIONAHA.109.874487 PMid:19801505 PMCid:PMC2784198
- Aubart M, ou P, Elie C et al. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major. J Pediatr Hematol Oncol 2016; 38: 497-502. https://doi.org/10.1097/MPH.0000000000000595 PMid:27548334
- Porter J, Elalfy M, taher A et al. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. Eur J Hematol 2016; 98: 280-288. https://doi.org/10.1111/ejh.12830 PMid:27859648
- Saliba A, El Rassi F, Taher A. Clinical monitoring and management of complications related to chelation therapy in patients with β- thalassemia. Expert Review of Hematology, 9:2, 151-168. https://doi.org/10.1586/17474086.2016.1126176 PMid:26613264
- Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008; 9(13): 2391-2402. https://doi.org/10.1517/146565188.8.131.521 PMid:18710363
- Nick H. Deferasirox (Exjade®, ICL670) Preclinical overview. Semin Hematol. 2007; 44: S12-15. https://doi.org/10.1053/j.seminhematol.2007.03.005
- Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol. 2009; 82(6): 454-457. https://doi.org/10.1111/j.1600-0609.2008.01204.x PMid:19191863 PMCid:PMC2730549
- Waldmeier F, Bruin GJ, Glaenzel U, et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos. 2010; 38(5): 808- 816. https://doi.org/10.1124/dmd.109.030833 PMid:20097723
- Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003; 10(12):1065-1076. https://doi.org/10.2174/0929867033457610 PMid:12678677
- Tanaka C. Clinical Pharmacology of Deferasirox. Clin Pharmacokinet (2014) 53:679–694. https://doi.org/10.1007/s40262-014-0151-4 PMid:24996374
- Lu M, Lin T, Chiang P, et al. Deferasirox–Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in b- Thalassemia Major. The Drug Monit 2017; 39: 185-191. https://doi.org/10.1097/FTD.0000000000000378 PMid:28141745
- Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873–880. PMid:16818273
- Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009; 82(6): 458-465. https://doi.org/10.1111/j.1600-0609.2009.01228.x PMid:19187278 PMCid:PMC2730551
- Taher A, Elalfy MS, Kusai AZ, et al. Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassemia: results from the ESCALATOR study.Eur J Haematol. 2011; 87(4):349-354. https://doi.org/10.1111/j.1600-0609.2011.01661.x PMid:21668501 PMCid:PMC3229710
- Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (icl670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107 (9):3455–3462. https://doi.org/10.1182/blood-2005-08-3430 PMid:16352812
- Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011; 118(4): 884-893. https://doi.org/10.1182/blood-2010-11-316646 PMid:21628399
- Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective epic study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557–566. https://doi.org/10.3324/haematol.2009.014696 PMid:19951979 PMCid:PMC2857545
- Porter JB, Elalfy MS, Taher AT, et al. Efficacy and safety of deferasirox at low and high iron burdens: results from the epic magnetic resonance imaging substudy. Ann Hematol. 2013;92(2):211–219. https://doi.org/10.1007/s00277-012-1588-x PMid:23086508 PMCid:PMC3542426
- Deugnier Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years. Gastroenterology. 2011;141(4):1202-1211, 1211.e1201-1203.
- Maggio A, Filosa A, Vitrano A et al. Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells, Molecules, and Diseases 2011; 47: 166–175. https://doi.org/10.1016/j.bcmd.2011.07.002 PMid:21843958
- JaiSwal S, Hishikar R, Khandwal O et al. Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients. Journal of Clinical and Diagnostic Research. 2017 Feb, Vol-11(2): FC01-FC03.
- Vichinsky E, El-Beshlawy A, AlZoebie A et al. Long term safety and efﬁcacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST). Pediatr Blood Cancer. 2017;64:e26507. https://doi.org/10.1002/pbc.26507 PMid:28296163
- Bollig C, Schell LK, Rücker G et al. Deferasirox for managing iron overload in people with Thalassaemia. Cochrane Database of Systematic Reviews 2017(8): 1-216. https://doi.org/10.1002/14651858.CD007476.pub3
- Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica 2011; 96:1055–8. https://doi.org/10.3324/haematol.2010.032862 PMid:21393329 PMCid:PMC3128226
- Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial t2* in patients with beta-thalassemia major. Haematologica. 2012;97(6):842–848. https://doi.org/10.3324/haematol.2011.049957 PMid:22271905 PMCid:PMC3366648
- Pennell DJ, Porter JB, Piga A, et al. A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β- Thalassemia Major and Iron Overload (CORDELIA). Blood 2012;121(21).
- Ho P J, Tay L, Teo J et al. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). Eur J Haem 2016; 9: 9-105.
- Poggi M, Sorrentino F, Pugliese P et al. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Ann Hematol (2016) 95:757–763. https://doi.org/10.1007/s00277-016-2633-y PMid:26957357
- EXJADE® (deferasirox) US Prescribing Information. 2013. Available from http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf
- Piga A, Fracchia S, Lai ME, et al. Effect of deferasirox on renal haemodynamics in patients with beta-thalassaemia: first interim analysis [abstract]. Haematologica. 2010; 95 (Suppl 2): 1798.
- Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in non-transfusion dependent thalassemia: 1- year results from a prospective, randomized, double-blind, placebo- controlled study. Blood. 2012;120(5):970–977. https://doi.org/10.1182/blood-2012-02-412692 PMid:22589472
- Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M. Fanconi syndrome due to deferasirox. American Journal of Kidney Diseases 2009;54 (5):931–4. https://doi.org/10.1053/j.ajkd.2009.03.013 PMid:19493602
- Osborne V, Davies M, Layton D, Shakir AS. Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England. Drug Saf (2018) 41:267–275. https://doi.org/10.1007/s40264-017-0606-2 PMid:29019038
- Bayhana T, Ünal S, Ünlü O, Küçüker H, Tutal Ad, Karabulut E et al. The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation. Hematology, 2017 VOL. 22, NO. 4, 248–251.
- Origa R, Piga A, Tartaglione I et al. Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent b- thalassemia and other anemias. AJH 2018; 1-3.
- Arandi N, Haghpanah S, Safaei S et al. Combination therapy – deferasirox and deferoxamine – in thalassemia major patients in emerging countries with limited resources. Transfusion Medicine 2015, 25, 8–12. https://doi.org/10.1111/tme.12188 PMid:25801075
- Lal, A., J. Porter, N. Sweeters, et al. 2013.Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. 50: 99–104. https://doi.org/10.1016/j.bcmd.2012.10.006 PMid:23151373 PMCid:PMC3592978
- Cassinerio, E., N. Orofino, A. Roghi, et al. 2014. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation n in thalassemia major. Blood Cells Mol Dis. 53: 164–167. https://doi.org/10.1016/j.bcmd.2014.04.006 PMid:24846580
- Aydinok, Y., A. Kattamis, M.D. Cappellini, et al. 2015. Effects of deferasirox–deferoxamine onmyocardial and liver iron in patients with severe transfusional iron overload. Blood 125: 3868–3877. https://doi.org/10.1182/blood-2014-07-586677 PMid:25934475 PMCid:PMC4490296
- Sridharan K, Sivaramakrishnan G. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Exp Rev Clinic Pharmacol 2018; 11 (6): 641–650. https://doi.org/10.1080/17512433.2018.1473760 PMid:29727586
- Farmaki, K., I. Tzoumari, C. Pappa. 2011. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol. Dis. 47: 33–40. https://doi.org/10.1016/j.bcmd.2011.03.007 PMid:21531154
- Totadri, S., D. Bansal, P. Bhatia, et al. 2015. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: a prospective, single center, open-label study. Pediatr. Blood Cancer 62: 1592–1596. https://doi.org/10.1002/pbc.25533 PMid:25820920
- Elalfy, M.S., A.M. Adly, Y. Wali, et al. 2015. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J. Haematol. 95: 411–420. https://doi.org/10.1111/ejh.12507 PMid:25600572
- Karami H, Kosaryan M, Amree Ah et al. Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusion dependent β-thalassemia major. Clinics and Practice 2017;7 (912): 11-14.
- Parakh N, Chandra J, Sharma S et al. Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With b-Thalassemia Major: An Experience From North India. J Pediatr Hematol Oncol 2017;39: 209–213. https://doi.org/10.1097/MPH.0000000000000780 PMid:28221264
- Pinto VM, Balocco M, Quintino S, Bacigalupo L, Gianesin B, Rizzi M, Malagò R, De Franceschi L, Forni GL. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients. Am J Hematol. 2018 Jul 22. doi: 10.1002/ajh.25222. [Epub ahead of print]. https://doi.org/10.1002/ajh.25222
- Inati A, kahale M, Sbeiti N, Cappellini MD, Taher AT, kousa S, Nasr T, Musalem KM, Abbas HA, Porter J. One‐year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatr Blood Cancer 2017; 64: 188-196. https://doi.org/10.1002/pbc.26213 PMid:27576370
- Yesilipek MA, Karasu G, Kaya Z, Kuskonmaz BB, Uygun V, Dag I, Ozudogru, ertem M. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major. Biol Blood Marrow Transplant 24 (2018) 608–632. https://doi.org/10.1016/j.bbmt.2017.11.006 PMid:29155313
- Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non- transfusion-dependent thalassemias. Haematologica. 2013;98(6):833- 44. https://doi.org/10.3324/haematol.2012.066845 PMid:23729725 PMCid:PMC3669437
- Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013;92(11):1485-93. https://doi.org/10.1007/s00277-013-1808-z PMid:23775581 PMCid:PMC3790249
- Taher AT, Cappellini MD, Aydinok Y, Porter JB, Karakas Z, Viprakasit V, et al. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells Mol Dis. 2016; 57:23-9. https://doi.org/10.1016/j.bcmd.2015.11.002 PMid:26852651
- Calvaruso G, Vitrano A, Di Maggio R, Lai E, Colletta G, Quota A, et al. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. Am J Hematol. 2015;90(7):634-8. https://doi.org/10.1002/ajh.24024 PMid:25809173
- Taher A, Vichinsky E, Musallam K, Cappellini M-D, Viprakasit V. Guidelines for the management of non-transfusion dependent thalassaemia (NTDT): Thalassaemia International Federation, Nicosia, Cyprus; 2013.
- Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919-29. https://doi.org/10.1111/j.1537-2995.2007.01416.x PMid:17880620
- Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36. https://doi.org/10.1159/000203853 PMid:8604584
- Trachtenberg FL, Gerstenberger E, Xu Y, Mednick L, Sobota A, Ware H, et al. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia. Qual Life Res. 2014; 23(8):2277-88. https://doi.org/10.1007/s11136-014-0671-2 PMid:24682717 PMCid:PMC4315322
- Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29(5):909-17. https://doi.org/10.1016/j.clinthera.2007.05.007 PMid:17697909
- Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia (Review). Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD012349. DOI: 10.1002/14651858.CD012349.pub2 https://doi.org/10.1002/14651858.CD012349.pub2
- Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168- 76. PMid:18028431 PMCid:PMC2268958
- Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-8. https://doi.org/10.1111/j.1365-2141.2006.06455.x PMid:17233848 PMCid:PMC1974786
- Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017;92(5):420-8. https://doi.org/10.1002/ajh.24668 PMid:28142202
- Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta thalassemia. Blood. 2010; 115(12): 2364-2371. https://doi.org/10.1182/blood-2009-04-217455 PMid:19996412
- Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in beta- thalassemia major patients with cardiac iron overload. Haematologica. 2011; 96(1): 48-54. https://doi.org/10.3324/haematol.2010.031468 PMid:21071497 PMCid:PMC3012764
- Pennell DJ, Porter JB, Piga A et al. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Am J Hematol. 2015; 90(2):91-6. https://doi.org/10.1002/ajh.23876 PMid:25345697